Effects of orlistat, a lipase inhibitor, on the pharmacokinetics of three highly lipophilic drugs (amiodarone, fluoxetine, and simvastatin) in healthy volunteers

Journal of Clinical Pharmacology

Volumn 43, Issue 4, 2003, Pages 428-435

  Zhi, Jianguo ^a   Moore, Rema ^a   Kanitra, Linda ^a   Mulligan, Thomas E ^a  

^a HOFFMANN LA ROCHE INC   (United States)

Author keywords

Amiodarone; Fluoxetine; Lipophilic drugs; Obesity; Orlistat; Simvastatin

Indexed keywords

AMIODARONE; DEETHYLAMIODARONE; DRUG METABOLITE; ENZYME INHIBITOR; FLUOXETINE; NORFLUOXETINE; PLACEBO; SIMVASTATIN; SIMVASTATIN ACID; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG;

ADULT; AGED; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN EXPERIMENT; INHIBITION KINETICS; MALE; NORMAL HUMAN; PLASMA; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AGED; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTILIPEMIC AGENTS; AREA UNDER CURVE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; FLUOXETINE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HALF-LIFE; HUMANS; LACTONES; LIPASE; MALE; MIDDLE AGED; SIMVASTATIN;

EID: 0037380717     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270003252236     Document Type: Article

References (18)

1. Zhi J, Melia AT, Guerciolini R, Chung J, Kinberg J, Hauptman JB, et al: Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther 1994;56:82-85.
2. Lucas KH, Kaplan-Machlis B: Orlistat - a novel weight loss therapy. Ann Pharmacother 2001;35:314-328.
3. Melia AT, Zhi J, Koss-Twardy SG, Min BH, Smith BL, Freundlich NL, et al: The influence of reduced dietary fat absorption induced by orlistat on the pharmacokinetics of digoxin in healthy volunteers. J Clin Pharmacol 1995;35:840-843.
4. Melia AT, Mulligan TE, Zhi J: The effect of orlistat on the pharmacokinetics of phenytoin in healthy volunteers. J Clin Pharmacol 1996;36:654-658.
5. Zhi J, Melia AT, Guerciolini R, Koss-Twardy SG, Passe SM, Rakhit A, et al: The effect of orlistat on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. J Clin Pharmacol 1996;36:659-666.
6. Weber C, Tam YK, Schmidtke-Schrezenmeier G, Jonkmann JH, van Brummelen P: Effect of the lipase inhibitor orlistat on the pharmacokinetics of four different antihypertensive drugs in healthy volunteers. Eur J Clin Pharmacol 1996;51:87-90.
7. Melia AT, Mulligan TE, Zhi J: Lack of effect of orlistat on the bioavailability of a single dose of nifedipine extended-release tablets (Procardia XL) in healthy volunteers. J Clin Pharmacol 1996;36:352-355.
8. Zhi J, Melia AT, Koss-Twardy SG, Min B, Guerciolini R, Freundlich NL, et al: The influence of orlistat on the pharmacokinetics and pharmacodynamics of glyburide in healthy volunteers. J Clin Pharmacol 1995;35:521-525.
9. Hartmann D, Guzelhan C, Zuiderwijk PB, Odink J: Lack of interaction between orlistat and oral contraceptives. Eur J Clin Pharmacol 1996;50:421-424.
10. Zhi J, Melia AT, Koss-Twardy SG, Arora S, Patel IH: The effect of orlistat, an inhibitor of dietary fat absorption, on the pharmacokinetics of β-carotene in healthy volunteers. J Clin Pharmacol 1996;36:152-159.
11. Melia AT, Koss-Twardy SG, Zhi J: The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers. J Clin Pharmacol 1996;36:647-653.
12. Oo CY, Akbari B, Lee S, et al: Effect of orlistat, a novel anti-obesity agent, on the pharmacokinetics and pharmacodynamics of pravastatin in patients with mild hypercholesterolaemia. Clin Drug Investig 1999;17:217-223.
13. Mück W, Adelmann H-G, Ruf T, et al: Lack of pharmacokinetic drug-drug interaction between orlistat and cerivastatin. Clin Drug Investig 2000;19:71-73.
14. Melia AT, Zhi J, Zelasko R, Hartmann D, Guzelhan C, Guerciolini R, et al: The interaction of the lipase inhibitor orlistat with ethanol in healthy volunteers. Eur J Clin Pharmacol 1998;54:773-777.
15. Zhi J, Moore R, Kanitra L, Mulligan TE: Pharmacokinetic evaluation of the possible interaction between selected concomitant medications and orlistat at steady-state in healthy subjects. J Clin Pharmacol 2002;42:1011-1019.
16. Schuirmann DJ: A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987;15:657-680.
17. Libersa CC, Brique SA, Motte KB, Caron JF, Guedon-Moreau LM, Humbert L, et al: Dramatic inhibition of amiodarone metabolism induced by grapefruit juice. Br J Clin Pharmacol 2000;49:373-378.
18. Physicians' Desk Reference, 53rd ed. Montvale, NJ: Medical Economics Co., 1999.